$6.72
1.05% day before yesterday
Nasdaq, Jan 02, 10:00 pm CET
ISIN
US30052C1071
Symbol
EOLS

Evolus, Inc. Stock price

$6.72
+0.20 3.07% 1M
-2.49 27.04% 6M
+0.07 1.05% YTD
-4.39 39.51% 1Y
-0.79 10.52% 3Y
+3.52 110.00% 5Y
-4.78 41.57% 10Y
-4.78 41.57% 20Y
Nasdaq, Closing price Fri, Jan 02 2026
+0.07 1.05%
ISIN
US30052C1071
Symbol
EOLS
Industry

Key metrics

Basic
Market capitalization
$435.6m
Enterprise Value
$537.9m
Net debt
$102.3m
Cash
$43.5m
Shares outstanding
64.8m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
1.5 | 1.4
EV/Sales
1.9 | 1.8
EV/FCF
negative
P/B
negative
Financial Health
Equity Ratio
2.4%
Return on Equity
-913.1%
ROCE
-25.0%
ROIC
-29.0%
Debt/Equity
-5.1
Financials (TTM | estimate)
Revenue
$285.8m | $304.2m
EBITDA
$-32.6m | $-12.3m
EBIT
$-38.1m | $-10.2m
Net Income
$-58.6m | $-29.4m
Free Cash Flow
$-57.9m
Growth (TTM | estimate)
Revenue
15.1% | 14.2%
EBITDA
-24.2% | 46.9%
EBIT
-20.6% | 62.6%
Net Income
-5.6% | 41.7%
Free Cash Flow
-124.5%
Margin (TTM | estimate)
Gross
65.8%
EBITDA
-11.4% | -4.0%
EBIT
-13.3%
Net
-20.5% | -9.7%
Free Cash Flow
-20.3%
More
EPS
$-0.9
FCF per Share
$-0.9
Short interest
10.0%
Employees
332
Rev per Employee
$800.0k
Show more

Is Evolus, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,082 stocks worldwide.

Evolus, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

13 Analysts have issued a Evolus, Inc. forecast:

11x Buy
85%
2x Hold
15%

Analyst Opinions

13 Analysts have issued a Evolus, Inc. forecast:

Buy
85%
Hold
15%

Financial data from Evolus, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
286 286
15% 15%
100%
- Direct Costs 98 98
31% 31%
34%
188 188
8% 8%
66%
- Selling and Administrative Expenses 216 216
13% 13%
76%
- Research and Development Expense 8.53 8.53
6% 6%
3%
-33 -33
24% 24%
-11%
- Depreciation and Amortization 5.44 5.44
3% 3%
2%
EBIT (Operating Income) EBIT -38 -38
21% 21%
-13%
Net Profit -59 -59
6% 6%
-20%

In millions USD.

Don't miss a Thing! We will send you all news about Evolus, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Evolus, Inc. Stock News

Positive
Seeking Alpha
19 days ago
Our portfolios underperformed during the quarter and trail year to date. Health care was the primary hindrance as a result of our underweight in biotech and negative stock selection. We have materially decreased our position as we evaluate this specific risk.
Neutral
Business Wire
about 2 months ago
NEWPORT BEACH, Calif.--(BUSINESS WIRE)--Evolus, Inc. (NASDAQ: EOLS), a performance beauty company with a focus on building an aesthetic portfolio of consumer brands, today reported the grant in November of non-qualified stock options to purchase an aggregate of 17,871 shares of Evolus and an aggregate of 45,063 restricted stock units (RSUs) of the company's common stock to 13 newly hired non-ex...
Neutral
Seeking Alpha
about 2 months ago
Evolus, Inc. ( EOLS ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Nareg Sagherian - Head of Global Investor Relations & Corporate Communications David Moatazedi - President, CEO & Director Rui Avelar - Chief Medical Officer and Head of Research & Development Tatjana Mitchell - Chief Financial Officer Conference Call Participants Annabel Samimy - Stifel, Nicolaus & Co...
More Evolus, Inc. News

Company Profile

Evolus, Inc. is a medical aesthetics company, which engages in the provision of medical aesthetic treatments and procedures. It offers products under the brand of Jeuveau. The company was founded by Scott Cannizzaro in November, 2012 and is headquartered in Newport Beach, CA.

Head office United States
CEO David Moatazedi
Employees 332
Founded 2012
Website www.evolus.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today